Antibiotics daptomycin interacts with S protein of SARS-CoV-2 to promote cell invasion of Omicron (B1.1.529) pseudovirus

References

• Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. Aaps J. 2021;23(1):14. doi: 10.1208/s12248-020-00532-2
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–14. doi: 10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• Atzrodt CL, Maknojia I, McCarthy RDP, et al. A guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS J. 2020;287(17):3633–3650. doi: 10.1111/febs.15375
   PubMed Web of Science ®Google Scholar
• Cai Y, Zhang J, Xiao T, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020;369(6511):1586–1592. doi: 10.1126/science.abd4251
   PubMed Web of Science ®Google Scholar
• Poltronieri P, Sun B, Mallardo M. RNA Viruses: RNA roles in pathogenesis, coreplication and viral load. Curr Genomics. 2015;16(5):327–335. doi: 10.2174/1389202916666150707160613
   PubMed Web of Science ®Google Scholar
• Wang MY, Zhao R, Gao LJ, et al. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol. 2020;10:587269. doi: 10.3389/fcimb.2020.587269
   PubMed Web of Science ®Google Scholar
• Djomkam ALZ, Olwal CO, Sala TB, et al. Commentary: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Front Oncol. 2020;10:1448. doi: 10.3389/fonc.2020.01448
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78(4):779–784.e5. doi: 10.1016/j.molcel.2020.04.022
   PubMed Web of Science ®Google Scholar
• Xia X. Domains and functions of spike protein in SARS-CoV-2 in the context of vaccine design. Viruses. 2021;13(1):109. doi: 10.3390/v13010109
   PubMed Web of Science ®Google Scholar
• Lippi G, Adeli K, Plebani M. Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants. Clin Chem Lab Med. 2021;60(3):338–342. doi: 10.1515/cclm-2021-1287
   Web of Science ®Google Scholar
• Ingraham NE, Ingbar DH. The omicron variant of SARS-CoV-2: understanding the known and living with unknowns. Clin Transl Med. 2021;11(12):e685. doi: 10.1002/ctm2.685
   PubMed Web of Science ®Google Scholar
• Callaway E. Heavily mutated omicron variant puts scientists on alert. Nature. 2021;600(7887):21. doi: 10.1038/d41586-021-03552-w
   PubMed Web of Science ®Google Scholar
• Xia S, Wang L, Jiao F, et al. SARS-CoV-2 omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors. Emerg Microbes Infect. 2023;12(1):2178241. doi: 10.1080/22221751.2023.2178241
   PubMed Web of Science ®Google Scholar
• Scarpa F, Azzena I, Locci C, et al. Molecular in-depth on the epidemiological expansion of SARS-CoV-2 XBB.1.5. Microorganisms. 2023;11(4):912. doi: 10.3390/microorganisms11040912
   PubMed Web of Science ®Google Scholar
• Castro-Lopes A, Correia S, Leal C, et al. Increase of antimicrobial consumption in a tertiary care hospital during the first phase of the COVID-19 pandemic. Antibiotics. 2021;10(7):778. doi: 10.3390/antibiotics10070778
   Web of Science ®Google Scholar
• Abu-Rub LI, Abdelrahman HA, Johar ARA, et al. Antibiotics prescribing in intensive care settings during the COVID-19 era: a systematic review. Antibiotics. 2021;10(8):935. doi: 10.3390/antibiotics10080935
   Google Scholar
• Lai CC, Chen SY, Ko WC, et al. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents. 2021;57(4):106324. doi: 10.1016/j.ijantimicag.2021.106324
   PubMed Web of Science ®Google Scholar
• Chedid M, Waked R, Haddad E, et al. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health. 2021;14(5):570–576. doi: 10.1016/j.jiph.2021.02.001
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Yang Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. 2020;9(1):153. doi: 10.1186/s13756-020-00819-1
   PubMed Web of Science ®Google Scholar
• Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27(4):520–531. doi: 10.1016/j.cmi.2020.12.018
   PubMed Web of Science ®Google Scholar
• Grau S, Echeverria-Esnal D, Gómez-Zorrilla S, et al. Evolution of antimicrobial consumption during the first wave of COVID-19 pandemic. Antibiotics. 2021;10(2):132. doi: 10.3390/antibiotics10020132
   Google Scholar
• Heidary M, Khosravi AD, Khoshnood S, et al. Daptomycin. J Antimicrob Chemother. 2018;73(1):1–11. doi: 10.1093/jac/dkx349
   PubMed Web of Science ®Google Scholar
• Fowler Jr VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–665. doi: 10.1056/NEJMoa053783
   PubMed Web of Science ®Google Scholar
• Bradley J, Glasser C, Patino H, et al. Daptomycin for complicated skin infections: a randomized trial. Pediatrics. 2017;139(3):e20162477. doi: 10.1542/peds.2016-2477
   PubMed Web of Science ®Google Scholar
• Holland TL, Cosgrove SE, Doernberg SB, et al. Ceftobiprole for treatment of complicated staphylococcus aureus bacteremia. N Engl J Med. 2023;389(15):1390–1401. doi: 10.1056/NEJMoa2300220
   PubMed Web of Science ®Google Scholar
• Raja A, LaBonte J, Lebbos J, et al. Daptomycin. Nat Rev Drug Discov. 2003;2(12):943–944. doi: 10.1038/nrd1258
   PubMed Web of Science ®Google Scholar
• King A, Phillips I. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother. 2001;48(2):219–223. doi: 10.1093/jac/48.2.219
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Pawlak J, Johnson LB. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int J Antimicrob Agents. 2010;36(1):69–72. doi: 10.1016/j.ijantimicag.2010.02.023
   PubMed Web of Science ®Google Scholar
• Silverman JA, Mortin LI, Vanpraagh ADG, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191(12):2149–2152. doi: 10.1086/430352
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhong K, Zhao J, et al. SARS-CoV-2 spike protein harnesses SNX27-mediated endocytic recycling pathway. MedComm. 2021;2(4):798–809. doi: 10.1002/mco2.92
   PubMedGoogle Scholar
• Weng G, Gao J, Wang Z, et al. Comprehensive evaluation of fourteen docking programs on protein-peptide complexes. J Chem Theory Comput. 2020;16(6):3959–3969. doi: 10.1021/acs.jctc.9b01208
   PubMed Web of Science ®Google Scholar
• Chen B, Deng YN, Wang X, et al. miR-26a enhances colorectal cancer cell growth by targeting RREB1 deacetylation to activate AKT-mediated glycolysis. Cancer Lett. 2021;521:1–13. doi: 10.1016/j.canlet.2021.08.017
   PubMed Web of Science ®Google Scholar
• Yang R, Huang B, A R, et al. Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro. Biosaf Health. 2020;2(4):226–231. doi: 10.1016/j.bsheal.2020.08.004
   PubMedGoogle Scholar
• Capcha JMC, Lambert G, Dykxhoorn DM, et al. Generation of SARS-CoV-2 spike pseudotyped virus for viral entry and neutralization assays: a 1-week protocol. Front Cardiovasc Med. 2021;7:618651. doi: 10.3389/fcvm.2020.618651
   PubMed Web of Science ®Google Scholar
• Chen J, Xu W, Li L, et al. Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins. Front Cell Infect Microbiol. 2022;12:967493. doi: 10.3389/fcimb.2022.967493
   PubMed Web of Science ®Google Scholar
• Zettl F, Meister TL, Vollmer T, et al. Rapid quantification of SARS-CoV-2-neutralizing antibodies using propagation-defective vesicular stomatitis virus pseudotypes. Vaccines (Basel). 2020;8(3):386. doi: 10.3390/vaccines8030386
   PubMed Web of Science ®Google Scholar
• Singh P, Mukherji S, Basak S, et al. Dynamic Ca2+ sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry. Cell Rep. 2022;39(3):110694. doi: 10.1016/j.celrep.2022.110694
   PubMed Web of Science ®Google Scholar
• Ye Y, Xia Z, Zhang D, et al. Multifunctional pharmaceutical effects of the antibiotic daptomycin. Biomed Res Int. 2019;2019:8609218. doi: 10.1155/2019/8609218
   PubMed Web of Science ®Google Scholar
• Kim PW, Sorbello AF, Wassel RT, et al. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Drug Saf. 2012;35(6):447–457. doi: 10.2165/11597460-000000000-00000
   PubMed Web of Science ®Google Scholar
• Portalatin GM, Chin JA, Foster B, et al. Daptomycin-induced acute eosinophilic pneumonia. Cureus. 2021;13(2):e13509. doi: 10.7759/cureus.13509
   PubMed Web of Science ®Google Scholar
• Uppal P, LaPlante KL, Gaitanis MM, et al. Daptomycin-induced eosinophilic pneumonia - a systematic review. Antimicrob Resist Infect Control. 2016;5(1):55. doi: 10.1186/s13756-016-0158-8
   PubMedGoogle Scholar
• Watts A, Gahona CCT, Raj K. Multifocal pneumonia amidst the global COVID-19 pandemic: a case of daptomycin-induced eosinophilic pneumonia. Cureus. 2021;13(6):e16002. doi: 10.7759/cureus.16002
   PubMed Web of Science ®Google Scholar
• Baskaran V, Lawrence H, Lansbury LE, et al. Co-infection in critically ill patients with COVID-19: an observational cohort study from England. J Med Microbiol. 2021;70(4):001350. doi: 10.1099/jmm.0.001350
   PubMed Web of Science ®Google Scholar
• Westblade LF, Simon MS, Satlin MJ. Bacterial coinfections in coronavirus disease 2019. Trends Microbiol. 2021;29(10):930–941. doi: 10.1016/j.tim.2021.03.018
   PubMed Web of Science ®Google Scholar
• Stogios PJ, Savchenko A. Molecular mechanisms of vancomycin resistance. Protein Sci. 2020;29(3):654–669. doi: 10.1002/pro.3819
   PubMed Web of Science ®Google Scholar
• Ma W, Zhang D, Li G, et al. Antibacterial mechanism of daptomycin antibiotic against Staphylococcus aureus based on a quantitative bacterial proteome analysis. J Proteomics. 2017;150:242–251. doi: 10.1016/j.jprot.2016.09.014
   PubMed Web of Science ®Google Scholar
• Howden BP, Davies JK, Johnson PDR, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23(1):99–139. doi: 10.1128/CMR.00042-09
   PubMed Web of Science ®Google Scholar
• Tabah A, Laupland KB. Update on staphylococcus aureus bacteraemia. Curr Opin Crit Care. 2022;28(5):495–504. doi: 10.1097/MCC.0000000000000974
   PubMed Web of Science ®Google Scholar
• Langford BJ, So M, Simeonova M, et al. Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis. Lancet Microbe. 2023;4(3):e179–e191. doi: 10.1016/S2666-5247(22)00355-X
   PubMedGoogle Scholar
• Abel R, Ramos MP, Chen Q, et al. Computational prediction of potential inhibitors of the main protease of SARS-CoV-2. Front Chem. 2020;8:590263. doi: 10.3389/fchem.2020.590263
   PubMed Web of Science ®Google Scholar
• Shekunov EV, Zlodeeva PD, Efimova SS, et al. Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: new tricks for old dogs. Antiviral Res. 2023;212:105575. doi: 10.1016/j.antiviral.2023.105575
   PubMed Web of Science ®Google Scholar
• Maffucci I, Contini A. In silico drug repurposing for SARS-CoV-2 main proteinase and spike proteins. J Proteome Res. 2020;19(11):4637–4648. doi: 10.1021/acs.jproteome.0c00383
   PubMed Web of Science ®Google Scholar
• Johnson BA, Hage A, Kalveram B, et al. Peptidoglycan-associated cyclic lipopeptide disrupts viral infectivity. J Virol. 2019;93(22):e01282–19. doi: 10.1128/JVI.01282-19
   PubMed Web of Science ®Google Scholar
• Chowdhury T, Baindara P, Mandal SM. LPD-12: a promising lipopeptide to control COVID-19. Int J Antimicrob Agents. 2021;57(1):106218. doi: 10.1016/j.ijantimicag.2020.106218
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Corey GR. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther. 2007;5(2):177–184. doi: 10.1586/14787210.5.2.177
   PubMed Web of Science ®Google Scholar
• Ayilya BL, Balde A, Ramya M, et al. Insights on the mechanism of bleomycin to induce lung injury and associated in vivo models: a review. Int Immunopharmacol. 2023;121:110493. doi: 10.1016/j.intimp.2023.110493
   PubMed Web of Science ®Google Scholar
• Ho SW, Jung D, Calhoun JR, et al. Effect of divalent cations on the structure of the antibiotic daptomycin. Eur Biophys J. 2008;37(4):421–433. doi: 10.1007/s00249-007-0227-2
   PubMed Web of Science ®Google Scholar
• Liu W, Li H. COVID-19: the CaMKII-like system of S protein drives membrane fusion and induces syncytial multinucleated giant cells. Immunol Res. 2021;69(6):496–519. doi: 10.1007/s12026-021-09224-1
   PubMed Web of Science ®Google Scholar